UR Medicine's Wilmot Cancer Institute | Strategic Alliance Partners

home / sap-partner / cancer-centers / university-of-rochester-wilmot-cancer-institute

The University of Rochester’s Wilmot Cancer Institute provides world-class cancer care and conducts pivotal cancer research. The goal is to prevent and conquer cancer through innovation in science, patient care, education, and community outreach. Serving a 27-county area in upstate New York, Wilmot features an 87-bed flagship cancer center, 13 outpatient locations, one of New York state’s largest bone marrow transplant programs and more.

Connect with us:

Latest from UR Medicine's Wilmot Cancer Institute

Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,

Dr. O'Regan on the RIGHT Choice Trial in HR+/HER2- Breast Cancer

March 21st 2023

Ruth M. O’Regan, MD, discusses how results from the phase 2 RIGHT Choice trial could influence the treatment paradigm in hormone receptor–positive, HER2-negative breast cancer.

Carla Falkson, MBChB, MMed, MD, professor, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center,

Dr. Falkson on the Use of Sacituzumab Govitecan in HR+/HER2- Breast Cancer

February 7th 2023

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

Anna Weiss, MD

Accuracy of Sentinel Lymph Node Biopsies Are Vital to Inform Treatment Decisions in Breast Cancer

January 27th 2023

The evolving treatment landscape across breast cancer has escalated the need for the accuracy of sentinel lymph node biopsies following treatment with neoadjuvant chemotherapy to correctly inform subsequent treatment decisions for patients.

State of Science Summit- Breast Cancer: Chaired by Anna Weiss, MD

State of Science Summit- Breast Cancer: Chaired by Anna Weiss, MD

December 15th 2022

State of Science Summit- Breast Cancer: Chaired by Anna Weiss, MD

Ruth M. O’Regan, MD

Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

August 9th 2022

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

Gina Mauro and Toni K. Choueiri, MD

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

February 21st 2022

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

Gina Mauro and Tanya Dorff, MD

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

February 18th 2022

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Carla Falkson, MBChB, MMed, MD

Personalized Medicine Shows Extended Reach Throughout Breast Cancer

November 18th 2021

Molecular markers, risk, and response are being used to better tailor escalated and de-escalated treatment approaches for women with breast cancer.

Carla Falkson, MBChB, MMed, MD

Dr. Falkson on the Potential to De-Escalate Chemotherapy in HER2+ Breast Cancer

November 12th 2021

Carla Falkson, MBChB, MMed, MD, discusses the potential to de-escalate chemotherapy in HER2-positive breast cancer.

Paul M. Barr, MD, of Wilmot Cancer Institute

Dr. Barr on the Implications of the Long-Term Results of the RESONATE-2 Trial in CLL

July 15th 2021

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul M. Barr, MD, of the Wilmot Cancer Institute

Dr. Barr on the Rationale for the Long-Term Evaluation of the RESONATE-2 Trial in CLL

June 30th 2021

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul M. Barr, MD

Dr. Barr on the Next Steps of the RESONATE-2 Trial in CLL

June 11th 2021

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO

ACCC Tool Gives Individualized Guidance for Geriatric Assessment Implementation in Patients With Cancer

June 2nd 2021

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.